Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD

Reem Karmali,Jeremy S. Abramson,Deborah M. Stephens,Jeffrey A Barnes,Jason Kaplan,Jane N. Winter,Shuo Ma,Juehua Gao,Adam M Petrich,Ephraim Hochberg,Tak Takvorian,Frank Kuhr,Lik Wee Lee,Valerie Nelson,Leo I. Gordon,Barbara Pro

Blood（2021）

Cited 1|Views6
No score
Abstract
BACKGROUND: Maintenance rituximab in MCL has improved survival and supports the exploration of maintenance with novel targeted agents. Ibrutinib is a BTK inhibitor approved for relapsed/refractory MCL. We report the final analysis of safety and efficacy of Ibrutinib maintenance (I-M) as monotherapy following chemo-immunotherapy induction for treatment-naive MCL in a multicenter phase II trial.
More
Translated text
Key words
mantle cell lymphoma,ibrutinib maintenance,cell lymphoma,ngs-mrd
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined